Aviceda Therapeutics

Aviceda Therapeutics is a late clinical-stage biotechnology company focused on developing novel drugs to treat patients with life-threatening diseases. Their approach centers on harnessing the body's natural immune system by modulating immune cell activity, specifically targeting chronic non-resolving inflammation. They do this by creating high-affinity ligands that bind to specific receptors on immune cells, enabling them to fine-tune the immune response in a targeted and precise manner.

Aviceda's research has led to the development of a proprietary technology platform called HALOS™ (High-Affinity Ligands of Siglecs), which forms the foundation for their innovative therapies. Their lead drug candidate, AVD-104, is a glyco-mimetic nanoparticle currently in Phase 2/3 clinical trials for the treatment of geographic atrophy, a leading cause of vision loss in age-related macular degeneration. Aviceda is expanding their pipeline to include other inflammatory diseases, such as diabetic macular edema, diabetic retinopathy, myelofibrosis, and lung inflammation.

Aviceda Therapeutics is a late clinical-stage biotechnology company focused on developing novel drugs to treat patients with life-threatening diseases characterized by chronic inflammation. They leverage the natural checkpoints of immune cells to modulate innate and adaptive immune activity, using their proprietary HALOS™ platform to create high-affinity ligands that target specific immune cells and pathways. Aviceda aims to develop transformative medicines for a variety of pathologies with currently unmet needs, including geographic atrophy, cancer, fibrosis, neurologic diseases, and others.

Aviceda Therapeutics promotes a collaborative and goal-oriented work environment, valuing highly motivated individuals who enjoy working as part of a team. They prioritize a cross-disciplinary approach, bringing together scientists, clinicians, and drug developers to tackle challenging diseases. Their commitment to innovation and a passion for improving patient lives are central to their culture.